Valsartan
Strives to synthesize a wide array of information, serving as a forum for discussion on litigation strategy, case criteria, and expert testimony.
Join the Litigation GroupValsartan
On July 13, 2018, the FDA announced a Class I recall of certain batches of Valsartan, a drug used to treat hypertension and heart failure. The Valsartan Litigation Group strives to synthesize a wide array of information, serving as a forum for discussion on litigation strategy, case criteria, and expert testimony. Members will be kept up to date on the science and applicable law on the Valsartan litigation, receiving sample pleadings and group materials that incorporate recommendations from experts.
- Meetings: The group meets at AAJ Annual and Winter conventions.
- Membership: The group is limited to AAJ Regular, Life, Sustaining, Leader Forum, and President’s Club member only.
- Annual Dues: $200 per first member of a firm/$50 for each additional member from the same firm.
Cochairs
Marlene Goldenberg | Goldenberg Law, PLLC, Minneapolis, MN
George Williamson | Farr Farr Emerich Hackett & Carr, PA, Punta Gorda, FL
Daniel Nigh | Levin Papntonio Raffert Proctor Buchanan O'Brien Barr & Mougey, PA, Pensacola, FL
Litigation Group members, visit AAJ's Community Center to connect with your colleagues on the list server, search discussion archives, download documents, update your list server settings, and more. Lit Group Member Login
